Alopecia

Low-dose oral minoxidil was not significantly associated with pericardial effusion among patients with alopecia, according to a study.

Leqselvi demonstrated clinically meaningful improvements long-term in adults with alopecia areata, Sun Pharma announced in a press release.

Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.

A newly published study found that an alopecia diagnosis precedes additional psychiatric and autoimmune diagnoses in affected patients.

A phase 2b study of rezpegaldesleukin for treating alopecia areata is underway following the drug’s success in other autoimmune diseases, according to a poster presented at the European Academy of Dermatology and Venerology Congress.

Down regulation of fibrotic processes and upregulation of keratinocyte proliferation was associated with low-dose metformin in patients with central centrifugal cicatricial alopecia, or CCCA, according to a study.

After 1 year’s worth of hair regrowth among patients treated with baricitinib for severe alopecia areata, treatment withdrawal resulted in a loss of benefit for almost all patients, according to a study.

Patients with alopecia treated with ritlecitinib reported high levels of satisfaction compared with those who received placebo, according to a study.

Patients with alopecia areata who were treated with deuruxolitinib experienced significant hair regrowth and reported satisfaction, according to a study.

The FDA has approved Leqselvi 8 mg tablets to treat severe alopecia areata in adults, Sun Pharma announced in a press release.